Some frequently asked questions
All your FAQs answered for the use of our products.
Have you seen any adverse reactions following the intra-articular injection of Arthramid® Vet?
We have not seen any abnormal reaction in the joints in the research population. There are a few reported cases of granulomatous reactions when PAAG has been used concurrently with IA corticosteroids.
Does the articular treatment need to be repeated at a specific interval or 1 dose is enough?
One dose is often enough but this is something we are wanting to find out. Anecdotally repeating the dose either at 4 weeks for partial responders or at 6 months has been beneficial.
If horse does not improve, what is the course of action?
We recommend trying to understand why it didn’t work (further imaging, synovial fluid, other factors ( e.g. foot imbalance, conformation, work surface)...etc...). This is different from horses that are partial responders. These horses should be re-examined at 4-6 weeks and another dose administered as there is strong evidence that the mechanical effect is dose-dependent. This is another aim of this study.
Can horses have NSAID’s or other anti-inflammatory medications concurrent with Arthramid®Vet?
NO NSAID, corticosteroids or other anti-inflammatory medication should be injected within 30 days of Arthramid®Vet. Oral NSAID's are ok.
Is it ok to inject several OA joints in the same horse?
In the field trial, several joints can be injected in the same horse.
Any trials on horses with no visible arthritis but blocking to joint with suspicion of sub-chondral bone damage and or stress fractures?
AV is indicated for horses with a proper diagnosis of OA. If these horses show signs of sub-chondral damage, we think that we can also treat such cases with Arthramid® Vet.
Is Arthramid® Vet indicated for osseous cyst-like lesions?
Practitioners have reported good results on cases with osseous cyst-like lesions in the stifle and fetlock.
Need expert advice?
Talk to the people in the know by contacting one of our Veterinary experts.